Results of the SPACE trial demonstrating the safety and efficacy of subcutaneous fremanezumab for the prevention of pediatric ...

Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

News and commentary from the world of neurology and neuroscience ...

The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...

Significantly reduced rate of acne and rosacea seen in patients treated with CGRPi mAbs vs triptans, topiramate. HealthDay News — For patients experiencing migraine, direct calcitonin gene-related ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...

EMERGE was an open-label trial that enrolled migraine patients who were undergoing treatment with an oral CGRP inhibitor for at least one month and experiencing an inadequate response to the oral CGRP ...

A surgeon is seen here in an undated stock photo. automation A new study shows that FDA-approved oral migraine drug atogepant is effective for relieving difficult-to-treat "medication overuse ...

For Cherise Irons, chocolate, red wine and aged cheeses are dangerous. So are certain sounds, perfumes and other strong scents, cold weather and thunderstorms. Stress and lack of sleep, too. She ...

Direct calcitonin gene-related peptide with monoclonal antibody exposure was also associated with significantly reduced rates of acne and rosacea compared with topiramate. HealthDay News — For ...